Alnylam Initiates RNAi Therapeutic Program for Pandemic Influenza
Health experts generally agree that an influenza pandemic could occur in the near future, and that such a pandemic could result in a widespread loss of human lives. The goal of Alnylam's RNAi therapeutic program for influenza infection will be to employ optimized siRNAs that silence highly conserved sequences required for viral replication across human and avian flu strains, thereby yielding a novel prevention and treatment option for world-threatening outbreaks of highly virulent strains of flu. Alnylam is currently in discussions with U.S. and world-wide health organizations to further advance its efforts to develop an RNAi therapeutic for the treatment of pandemic flu.
Other news from the department science
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.